KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma -the IT-MATTERS study.

Eyal Talor, József Tímár, Philip Lavin, John Cipriano, Dusan Markovic, Andrea Ladányi, Andrey Karpenko, Igor Bondarenko, Srboljub Stosic, Hrvoje Sobat, Aliaksandr Zhukavets, Nazim Imamovic, Chih-Yen Chien, Magdalena Bankowska-Wozniak, Mihály Kisely, Rajko Jovic, James Edward Massey Young, Sheng-Po Hao

Pathol Oncol Res 31 1612084

PMID40191245
PMCIDPMC11968324
DOI10.3389/pore.2025.1612084
发表日期2025-04-07
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图。
摘要

摘要

The randomized controlled pivotal phase 3 study evaluated efficacy and safety of neoadjuvant complex biologic, Leukocyte Interleukin Injection (LI), administered for 3 consecutive weeks pre-surgery, in treatment naïve resectable locally advanced primary squamous cell carcinoma of oral cavity and soft palate. Randomization 3:1:3 to LI+/-CIZ (cyclophosphamide, indomethacin, and zinc)+SOC, or SOC (standard of care) alone. LI-treated patients received 400 IU (as interleukin-2 equivalent; 200 IU peritumorally, 200 IU perilymphatically) sequentially, daily 5 days/week for 3 weeks before surgery. All subjects were to receive SOC. Post-surgery, patients with low risk for recurrence were to receive radiotherapy, while those with high risk received concurrent chemoradiotherapy. Median follow-up was 56 months. There were 923 ITT (Intent-to-Treat) subjects (380 ITT low-risk and 467 ITT high-risk). Pre-surgery objective early response (45 objective early responders; 5 complete responses [CRs], 40 partial responses [PRs], confirmed by pathology at surgery. LI (+/- CIZ) had 8.5% objective early responders (45/529 ITT) and 16% objective early responders (34/212 ITT low-risk) vs. no reported SOC objective early responders (0/394 ITT). Objective early responders significantly lowered death rate to 22.2% (ITT LI-treated), 12.5% (ITT low-risk LI + CIZ + SOC), while the ITT low-risk SOC death rate was 48.7%. Thus, objective early response impacted overall survival (OS); proportional hazard ratios were 0.348 (95% CI: 0.152-0.801) for ITT low-risk LI-treated, 0.246 (95% CI: 0.077-0.787) for ITT low-risk LI + CIZ + SOC. ITT low-risk LI + CIZ + SOC demonstrated significant OS advantage vs. ITT low-risk SOC (unstratified log-rank p = 0.048; Cox hazard ratio = 0.68; 95% CI: 0.48-0.95, Wald p = 0.024 [controlling for tumor stage, tumor location, and geographic region]). Absolute OS advantage increased over time for ITT low-risk (LI + CIZ + SOC)-treated vs. ITT low-risk SOC: reaching 14.1% (62.7% vs. 48.6%) at 60 months, with 46.5 months median OS advantage (101.7 months vs. 55.2 months), respectively. Quality of life benefit for complete responders sustained for >3 years post LI treatment. Percent treatment-emergent adverse events were comparable among all treated groups. No excess safety issues were reported for LI over SOC alone post-surgery. NCT01265849, EUDRA:2010-019952-35.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Study schema from enrollment through disease-directed therapy. Abbreviations: CIZ, cyclophosphamide, indomethacin, zinc; CRTx, chemoradiotherapy; IV, intravenous; po, orally; RTx, radiotherapy; TID, three times daily.
非 KM Figure
FIGURE 2Overall survival Kaplan-Meier plot of ITT low-risk patients in the 3 treatment groups (n = 380). Abbreviations: CIZ, cyclophosphamide, indomethacin, zinc; ITT, intent-to-treat; OS, overall survival; SOC, standard of care. Multikine, LI (Leukocyte Interleukin, Injection). NOTE: blue line depicts OS for Group 1 (LI + CIZ + SOC), which at all times separated from and above Group 3 (SOC only, control) curve (green), red line depicts OS for Group 2 (LI + SOC).
非 KM Figure
FIGURE 3Kaplan-Meier plot of overall survival in ITT low-risk responding* and non-responding subjects treated with LI + CIZ + SOC and SOC alone (n = 326). Abbreviations: CIZ, cyclophosphamide, indomethacin, and zinc as multivitamin supplement; ITT, intent-to-treat; LI, Leukocyte Interleukin, Injection; SOC, standard of care. *Response per RECIST v.1.0 (and confirmed by pathology at surgery).
非 KM Figure
FIGURE 4Kaplan-Meier plot of overall survival in overall ITT Group 1 (A) (N = 347) and Group 3 (B) (N = 353): AJCC (TN) PSD, no change, and upstage.
非 KM Figure